🇺🇸 FDA

Intelligence · Patents

Recently granted patents

New US pharmaceutical patent grants from the past 12 months — competitive surveillance for BD and IP teams.

Patents
632

Quick answer

632 pharmaceutical patents in our USPTO index were granted within the past year. Browse by grant date with links to applicant company portfolios and related drug profiles.

  1. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12377115

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12377026

    Dental adhesive material kit

    KURARAY NORITAKE DENTAL INC. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12377151

    Immobilized endoglycosidase fusion protein and use thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12370245

    ALK polypeptides and methods of use thereof

    Elicio Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12371500

    Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12371665

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12370255

    Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12371420

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12371499

    Method of treating cancer using anti-AV8 antibodies

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12370266

    Polymer composite nanomaterial encapsulation system

    Core Quantum, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    HALOZYME, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12370142

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12370194

    Metalloenzyme inhibitor compounds

    Eikonizo Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12370232

    Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition

    Poly Gain Pte Ltd · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12370229

    Methods of treating bladder cancer

    CG ONCOLOGY, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12370261

    Chimeric peptides for antisense delivery

    Sarepta Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12370192

    Azole-fused pyridazin-3(2H)-one derivatives

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12370241

    Nasal powder formulation for treatment of hypoglycemia

    Amphastar Pharmaceuticals, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12371333

    Purification of clinoptilolite

    Revelation Health LLC · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12370256

    Activation of resident memory T cells for the treatment of cancer

    Regents of the University of Minnesota · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12371503

    Methods of treatment using a leptin receptor agonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12371414

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12369604

    Methods of inhibition with microbial strains and antibiotics

    MICROBIAL DISCOVERY GROUP, LLC · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12370206

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12370196

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12370267

    Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)

    Northwestern University · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12371445

    Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12371466

    Chimeric antigen receptor and methods of use thereof

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12370270

    Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12370257

    Materials and methods of treating MHC-I-opathy risk haplotypes

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12370181

    Regimens of estrogen receptor antagonists

    Olema Pharmaceuticals, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12365711

    TGFβ signal convertor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12365889

    Tunable nanoscale cages from self-assembling DNA and protein building blocks

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12365664

    Small molecule inhibitors of SRC tyrosine kinase

    The Board of Regents of the University of Texas System · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12365875

    Methods for generating skeletal muscle progenitor cells

    The Regents of the University of California · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12364765

    Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12364688

    NSD family inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How recent are these patent grants?

This hub lists published patents with a grant date within the last 365 days, ordered newest first.

Which patent classes are included?

We index USPTO PatentsView records with pharmaceutical CPC classifications A61K and A61P linked to tracked assignee companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.